30/04/2016 01:16:54 1-888-992-3836 (toll free) Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
04/28/20166:11PMDJNGilead Reports Drop in Hepatitis C Drug Revenue -- Update
By Lisa Beilfuss Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations, suggesting competition is eating into the company's hold on a hot corner of the drug market. Shares in the company slid 6.6% in after-hours trading... More...>>
04/28/20165:00PMDJNGilead Reports Drop in Hepatitis C Drug Revenue
Gilead Sciences Inc. said revenue from its hepatitis C drugs fell 5.6% in the first quarter as sales of Harvoni and Sovaldi fell short of expectations. Shares in the company slid 5.3% in after-hours trading. The Foster City, Calif., biopharmaceutical company dominates the market for treating hepatitis C, inflammation of... More...>>
04/28/20168:50AMDJNAbbVie Agrees to Buy Stemcentrx, Reports Jump in Earnings
AbbVie Inc. agreed to acquire Stemcentrx in a roughly $5.8 billion cash-and-stock deal that expands its pipeline of cancer treatments. With the acquisition, which includes additional potential milestone payments of as much as $4 billion, AbbVie gains Semcentrx's Rova-T lung cancer treatment, a biomarker-specific therapy... More...>>
04/28/20168:00AMPRNUSChristina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake"
Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake" Christina Applegate Shares Personal Struggle with Insomnia and Encourages Others to Educate Themselves about the Wake and Sleep Systems in the Brain PR Newswire KENILWORTH, N.J., April 28, 2016 KENILWORTH, N.J., April 28, 2016... More...>>
04/27/20168:00AMPRNUSMerck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health E...
Merck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic Tim McGraw, S. Epatha Merkerson and Chef Leticia Call on the Nearly 30 Million Americans Living with Diabetes to Tell Their Stories PR Newswire KENILWORTH, N.J., April 27, 2016 KENILWORTH... More...>>
04/27/20161:00AMPRNUSJournal of the American Medical Association Publishes Phase III Data From Allergic Asthma Trial With ALK's House Dust Mite SL...
Journal of the American Medical Association Publishes Phase III Data From Allergic Asthma Trial With ALK's House Dust Mite SLIT-tablet, ACARIZAX® PR Newswire HØRSHOLM, Denmark, April 27, 2016 HØRSHOLM, Denmark, April 27, 2016 /PRNewswire/ -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that The Journal... More...>>
04/26/201611:39AMPRNUSJournal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SL...
Journal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SLIT-tablet, ACARIZAX® PR Newswire HØRSHOLM, Denmark, April 26, 2016 HØRSHOLM, Denmark, April 26, 2016 /PRNewswire/ -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that The Journal... More...>>
04/26/20164:10AMDJNBayer Posts 13% Jump in Net Profit
FRANKFURT—German health care company Bayer AG reported a 13.3% jump in net profit for the first quarter of 2016, driven by strong earnings growth at the group's pharmaceuticals division, while confirming a cautious guidance for the full year. Net profit for the period ended March 31 was €1.51 billion ($1.70... More...>>
04/19/20165:00PMBWMerck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System
Non-Invasive Device Helps Diagnose Bovine Respiratory Disease Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced plans to acquire worldwide rights for the Whisper® Veterinary Stethoscope System from Minnesota-based Geissler Companies. The Whisper Veterinary Stethoscope... More...>>
04/19/20162:05PMBWMerck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is proud to be a part of the Blueprint PD-L1 Assay Comparison Project, an important initiative to compare several new diagnostic tests for the immune biomarker PD-L1 in non-small cell lung cancer (NSCLC). Merck believes strongly in the importance of... More...>>
04/18/20168:00AMBWMerck Receives Breakthrough Therapy Designation from U.S. Food & Drug Administration for KEYTRUDA® (pembrolizumab) in Classi...
Fourth Designation for KEYTRUDA Follows Breakthrough Status in Advanced Melanoma, Non-Small Cell Lung Cancer, and Colorectal Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA®... More...>>
04/17/20168:50PMDJNBristol's Opdivo Shows Benefits in Cancer Immunotherapy Trial
More than one-third of advanced melanoma patients treated in a study of Bristol-Myers Squibb Co.'s Opdivo have survived at least five years, researchers said, providing fresh evidence of the durable benefit cancer immunotherapy agents have for some patients. The study followed 107 patients who were enrolled in an... More...>>
04/16/20161:00AMBWMerck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir & Grazoprevir) in Chronic Hepatitis C Patient Populatio...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood disorders (C-EDGE IBLD) and in patients with... More...>>
04/14/20161:00AMBWMerck’s ZEPATIER™ (Elbasvir & Grazoprevir) Showed Superiority on Efficacy & Safety Endpoints Compared to Sofosbuvir Plus ...
Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress™ 2016 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from C-EDGE Head-to-Head, the company’s comparative... More...>>
04/13/20168:50AMDJNFDA to Review Merck's Keytruda for Head and Neck Cancer
The U.S. Food and Drug Administration has accepted Merck & Co.'s supplemental biologics license application for its immunotherapy cancer drug for patients with head and neck cancer, the pharmaceutical company said Wednesday. The FDA granted pembrolizumab, or Keytruda, priority review status with a target action... More...>>
04/13/20168:36AMDJNFDA to Review Merck's Keytruda for Head and Neck Cancer
By Anne Steele The U.S. Food and Drug Administration has accepted Merck & Co.'s supplemental biologics license application for its immunotherapy cancer drug for patients with head and neck cancer, the pharmaceutical company said Wednesday. The FDA granted pembrolizumab, or Keytruda, priority review status with... More...>>
04/13/20167:00AMBWFDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head ...
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with recurrent... More...>>
04/13/20161:15AMGLOBELicense application for investigational house dust mite SLIT-tablet accepted for review by FDA
COPENHAGEN, Denmark, April 13, 2016 (GLOBE NEWSWIRE) -- Today, ALK's (ALKB:DC / OMX: ALK B / AKABY / AKBLF) partner for North America, MSD (known as Merck (NYSE: MRK) in the United States and Canada), announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for its... More...>>
04/08/20168:00AMBWMerck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, May 5. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>>
04/07/20166:40PMDJNFDA Panel Backs Approval of Liver-Disease Drug
A U.S. Food and Drug Administration advisory panel recommended the agency approve a new drug for the treatment of a rare liver condition—the latest milestone in a rapidly growing market for liver-disease drugs. The FDA's panel of outside advisers voted 17-0 Thursday that there was substantial evidence to support... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20160430 05:16:55